Comparative efficacy of intralesional 5 flurouracil and intralesional triamcinolone acetonide in localized plaque psoriasis.
5-FU
intralesional treatments
psoriasis
triamcinolone
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
14
08
2022
received:
31
07
2021
accepted:
28
08
2022
pubmed:
31
8
2022
medline:
5
11
2022
entrez:
30
8
2022
Statut:
ppublish
Résumé
Psoriasis is a papulosquamous disorder that causes significant social and psychological trauma to the patient. It is characterized by the presence of erythematous, indurated plaques covered with silvery-white scales. Despite the availability of several systemic agents that have been approved for the treatment of psoriasis, usually there are some residual lesions and there is a need to treat them for cosmetic reasons or symptomatic control. 1. Treatment of resistant localized psoriatic plaques or residuals after systemic treatment. 2. Recently, some intralesional agents have been used successfully for the treatment of psoriatic plaques as 5-FU, methotrexate, and botulinum toxin type-A, and nearly for four decades, no study focused on the effect of intralesional corticosteroids in the treatment of these psoriatic plaques. We decided to highlight their role and compare intralesional Triamcinolone to intralesional 5-FU regarding efficacy and safety in the treatment of plaque psoriasis. This study included 24 patients with localized plaque psoriasis. Each patient was treated by split-body therapy where one psoriatic plaque was treated with intralesional 5FU and another plaque with intralesional TAC. A total of three injections were given at 2-week intervals and follow up was regularly every 2 weeks up to 12 weeks. There was a statistically significant difference between both groups (p = 0.008) as the response rate on 5-FU side was 12.5% with no response, 29.2% with a moderate response, 41.7% with an excellent response, and 16.7% with a complete clearance, while on the TAC side it was16.7% with a moderate response, 20.8% with an excellent response and 62.5% with a complete clearance. Hyperpigmentation was the most irritating side effect of 5-FU that occurred. Pain, during and after injection, was greater in 5-FU group. Hypopigmentation and atrophy only occurred in TAC group in some patients but it seems to be reversible and not disfiguring. 1-Intralesional TAC injection may have more efficacy and less side effects than 5-FU injection in the treatment of localized plaque psoriasis. Hyperpigmentation and pain were the most irritating side effects of 5-FU 2-Intralesional TAC can be effective in the treatment of localized psoriatic plaques with minimal side effects, especially in patients not suitable for systemic agents.
Substances chimiques
Triamcinolone Acetonide
F446C597KA
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15796Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Baliwag J, Barnes DH, Johnston A. Cytokines in psoriasis. Cytokine. 2015;73(2):342-350.
Hjuler K, Iversen L, Rasmussen M, Kofoed K, Skov L, Zachariae C. Localization of treatment-resistant areas in patients with psoriasis on biologics. Br J Dermatol. 2019;181(2):332-337.
Ghorpade AK. Naevoid Blaschkoid psoriasis. Indian J Dermatol Venereol Leprol. 2010;76(4):449.
Ahluwalia A. Topical glucocorticoids and the skin-mechanisms of action: an update. Mediators Inflamm. 1998;7(3):183-193.
Wang T-S, Tsai T-F. Intralesional therapy for psoriasis. J Dermatol Treat. 2013;24(5):340-347.
Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330-338.
Ceilley RI. Mechanisms of action of topical 5-fluorouracil: review and implications for the treatment of dermatological disorders. J Dermatol Treat. 2012;23(2):83-89.
Mahajan B, Singla M. Evaluation of intralesional 5% 5-fluorouracil in resistant localized plaque psoriasis. Indian Dermatol Online J. 2014;5(3):287-290.
Khattab F, Samir MA. Botulinum toxin type-A versus 5-fluorouracil in the treatment of plaque psoriasis: comparative study. J Cosmet Dermatol. 2021;20:3128-3132.
Attia HO, Kawy FA, Hafiz HS. Intralesional methotrexate vs intralesional 5-fluorouracil in the treatment of localized plaque psoriasis: a comparative clinical and dermoscopic study. Sci J Al-Azhar Med Faculty, Girls. 2019;3(3):643.
Pelzig A, Baer RL. Treatment of psoriasis with intralesional injections of triamcinolone. JAMA. 1960;173(8):898-900.
Pariser H, Murray PF. Intralesional injections of triamcinolone: effects of different concentrations on psoriatic lesions. Arch Dermatol. 1963;87(2):183-187.
Readett M. Intralesional triamcinolone acetonide in the treatment of psoriasis. Br J Dermatol. 1961;73(3):107-109.
Hasegawa J, Livingston W. The intralesional use of triamcinolone acetonide in psoriasis: a double blind study. Arch Dermatol. 1962;85(2):258-260.